ABC Content Board

The abc of trending content

AMGN Gets FDA Nod, Uncertainty Ends For CEMP, Clock Is Ticking For ANTH


Anthera Pharmaceuticals Inc. (ANTH) is all set to report top line data from a phase III study of Blisibimod for the treatment of systemic lupus erythematosus, dubbed CHABLIS-SC1, before November 11, 2016.

The top line data from the CHABLIS-SC1 study will include the primary endpoint evaluation, the Systemic Lupus Erythematosus Responder Index (SRI-6) as well as safety and tolerability data from the study.

The clinical trial results can make or break a drug company. Click here for some of the biotech stocks, which are slated to report clinical trial results in the coming months.

ANTH closed Friday’s trading at $2.35, up 11.37%.

The FDA on Friday approved the expanded use of Amgen’s (AMGN) Enbrel to treat pediatric patients aged 4-17 with chronic moderate-to-severe plaque psoriasis.

Enbrel in combination with Methotrexate or used alone is already indicated for rheumatoid arthritis,…


Read the full article from the Source…

Back to Top